Pfizer (PFE) Market Cap (1999 - 2026)
Pfizer (PFE) market cap from Nov 1, 1999 to Jul 20, 2026. The current Pfizer (PFE) market cap is $141B. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Market Cap
Pfizer (PFE) Market Cap CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | -1.46% |
| 3 Years TTM | -16.06% |
| 5 Years TTM | -6.71% |
| 10 Years TTM | -2.78% |
| All Time TTM | -1.56% |
Annual Market Cap change of Pfizer (PFE)
| Year | Market Cap | Change |
|---|---|---|
| 2026 | $141B | -0.50% |
| 2025 | $142B | -5.85% |
| 2024 | $150B | -7.51% |
| 2023 | $163B | -43.42% |
| 2022 | $287B | -13.26% |
| 2021 | $331B | +61.92% |
| 2020 | $205B | -0.76% |
| 2019 | $206B | -15.28% |
| 2018 | $243B | +18.97% |
| 2017 | $205B | +9.40% |
| 2016 | $187B | -1.04% |
| 2015 | $189B | +0.98% |
| 2014 | $187B | -2.18% |
| 2013 | $191B | +8.09% |
| 2012 | $177B | +10.91% |
| 2011 | $160B | +19.63% |
| 2010 | $133B | +3.35% |
| 2009 | $129B | +34.93% |
| 2008 | $96B | -22.09% |
| 2007 | $123B | -12.24% |
| 2006 | $140B | +11.06% |
| 2005 | $126B | -13.28% |
| 2004 | $145B | -23.89% |
| 2003 | $191B | +15.57% |
| 2002 | $165B | -23.29% |
| 2001 | $215B | -13.37% |
| 2000 | $248B | +41.80% |
| 1999 | $175B | N/A |
Comparison Pfizer (PFE) market cap with competitors
Pfizer (PFE) market cap is $140.85B.
| Ticker | Name | Market Cap | Upside |
|---|---|---|---|
| LLY | Lilly(Eli) & Company | $1.03T | +634.25% |
| JNJ | Johnson & Johnson | $594.97B | +322.41% |
| ABBV | Abbvie Inc | $432.22B | +206.86% |
| AZN | Astrazeneca plc | $295.54B | +109.83% |
| MRK | Merck & Co Inc | $291.57B | +107.00% |
| NVS | Novartis AG | $288.93B | +105.13% |
| NVO | Novo Nordisk | $224.93B | +59.69% |
| AMGN | AMGEN Inc | $193.39B | +37.30% |
| GILD | Gilead Sciences Inc | $163.57B | +16.13% |
| BMY | Bristol-Myers Squibb Company | $119.63B | -15.07% |
| SNY | Sanofi | $105.20B | -25.31% |
| GSK | GSK Plc | $104.78B | -25.61% |
| BIIB | Biogen Inc | $29.03B | -79.39% |
| GRFS | Grifols SA | $4.91B | -96.52% |
| OGN | Organon & Company | $3.54B | -97.48% |
| AMRN | Amarin Corp | $303.37M | -99.78% |
| SCLX | Scilex Holding Company | $78.29M | -99.94% |
| MIRA | Mira Pharmaceuticals Inc | $39.50M | -99.97% |
| NSRX | Nasus Pharma Ltd | $28.10M | -99.98% |
| MDCXW | Medicus Pharma Ltd warrant | $19.20M | -99.99% |
| MDCX | MDCorp | $13.93M | -99.99% |